Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2021 Jul 15;12:690392. doi: 10.3389/fphar.2021.690392

Bibliometric and Visual Analysis of Vascular Calcification Research

Qian Dong 1,†, Qingchun Liang 2,†, Ying Chen 1, Jinhe Li 2, Lihe Lu 3, Xiongqing Huang 1,*, Qin Zhou 1,*
PMCID: PMC8319769  PMID: 34335257

Abstract

Background: Extensive studies related to vascular calcification (VC) were conducted in recent years. However, no bibliometric analysis has systematically investigated this topic. Our study aimed to determine the hotspots and frontiers of VC research in the past decade and provide a reference for future scientific research directions and decision-making in the VC field.

Methods: VC studies were acquired from the Web of Science Core Collection. Bibliometric and visual analyses were performed using CiteSpace, VOSviewer, and Microsoft Excel software.

Results: A total of 8,238 English articles on VC research published in 2011–2020 were obtained. In the past decade, annual publications and citations showed a significant growth trend, especially in 2018–2020. The most productive country, institution, journal and author are the United States, the University of California System, PLOS ONE, and Budoff MJ, respectively. The most frequently cited country, journal, and author are the United States, Journal of the American College of Cardiology, and Floege J, respectively. “Vascular calcification,” “atherosclerosis,” “chronic kidney disease,” and “cardiovascular disease” are the primary keywords. The burst keywords “revascularization,” “calciprotein particle,” “microRNA,” and “microcalcification” are speculated to be the research frontiers.

Conclusion: The main research hotspots in the VC field are the molecular mechanisms and prognosis of VC in patients with chronic kidney disease or cardiovascular disease. In addition, endovascular therapy and the development of new drugs targeting signal pathways for VC will become the focus of future research. Moreover, non-coding RNAs related to the diagnosis and treatment of VC are great research prospects.

Keywords: vascular calcification1, chronic kidney disease2, atherosclerosis3, vascular smooth muscle cell4, citespace5, VOSviewer6, bibliometrics7

Introduction

Vascular calcification (VC) is defined as the abnormal deposition of calcium and phosphorus minerals in the arterial intima or media that can lead to reduced vascular wall compliance (Gourgas et al., 2018). VC is a common pathological manifestation of aging, atherosclerosis, hypertension, diabetes, and chronic kidney disease (CKD) (Poterucha and Goldhaber, 2016; Li et al., 2019). Among pathological conditions, CKD is most closely related to VC. Compared with the general population, CKD patients have a higher incidence and faster progression of VC (Shobeiri et al., 2010; Zhang et al., 2020). In addition, VC plays a key role in the pathogenesis of aortic valve disease, coronary artery disease and peripheral arterial disease (Park et al., 2021). Furthermore, its progression is highly related to increased cardiovascular morbidity and mortality (Shobeiri et al., 2010). Thus, we must pay closer attention to the occurrence and development of VC.

VC was previously thought to involve the passive deposition of calcium phosphate crystals within the vessel wall. However, since the 1990s, extensive studies have shown that VC is an active and regulated process similar to bone development (Shioi et al., 1995; Kong et al., 2018). Recent studies suggested that VC is a complicated biological process, depending on balance between calcification promoters and inhibitors (Lee et al., 2020). The calcification promoters include inflammation, oxidative stress, apoptosis, hyperparathyroidism and hyperphosphatemia (Yan et al., 2011; Song et al., 2017; Zhang et al., 2020). They can promote the differentiation of vascular smooth muscle cells (VSMCs) into osteogenic cells (Shao et al., 2010; Dong et al., 2020). In contrast, it is well-known that calcification inhibitors including PPi, MGP, fetuin-A, osteoprotegerin, osteopontin, Klotho, magnesium and SNF472 inhibit the differentiation of VSMCs into osteoblasts (Bäck et al., 2019; Perelló et al., 2020). VC occurs when the expression of calcification promoting factors is increased or the expression of calcification inhibitors is decreased. Increasing evidence has shown that the osteogenic differentiation of VSMCs is the core mechanism of VC. Multiple studies conducted in atherosclerosis or CKD animal models and human samples have suggested the existence of ossification/chondral metaplasia and the expression of osteoblasts in the pathological arterial wall (Rattazzi et al., 2005; Speer et al., 2009). However, the exact molecular mechanisms underlying VC remain unclear.

Continuous studies of VC mechanisms have made great contributions to the exploration of the best treatment to improve patient prognosis. However, no efficient therapy is approved for the treatment of VC until now, although various treatment strategies targeting pathological conditions (CKD, cardiovascular disease and osteoporosis) are available. These interventions include phosphate binders, sodium thiosulphate, calcimimetics, vitamin K, vitamin D, myoinositol, denosumab, and tissue-nonspecific alkaline phosphatase inhibitors (Singh et al., 2021). Several studies to date have demonstrated that the overexpression or inhibition of non-coding RNAs (ncRNAs) may provide promising avenues for VC therapy. Recently developed genome editing technologies, such as base editors and Cas13, can be used for VC treatment by targeting ncRNAs (Ryu et al., 2021). Additionally, emerging evidence has demonstrated that autophagy and lysosomal function are positive regulators of VC. Thus, the development of novel, highly selective autophagy or lysosome inducers may provide new therapeutic strategies (Neutel et al., 2020). In short, treatments based on molecular mechanisms, cellular signaling pathways, and gene regulation have extraordinary research value and therapeutic potential. However, an effective treatment strategy for VC has yet to be determined.

Several methods can be used to conduct a quantitative analysis of the literature, such as a traditional review, a main path analysis (Yu and Pan, 2021), and bibliometrics. Among them, bibliometrics is a comprehensive knowledge system that integrates mathematics, statistics, and philology and focuses on publication quantity. Bibliometrics has been widely employed to explore development trends and research frontiers in various research fields (Chen, 2006). CiteSpace software is a document visualization analysis software that was gradually developed under the background of bibliometrics and data visualization. It can display the basic knowledge and hotspots of a certain research field through visualization and predict evolution trends and research frontiers (Chen et al., 2012).

VOSviewer is a bibliometric software used to construct relationship networks and visualize data. Its outstanding feature is that it has strong graphics capabilities and is suitable for processing large-scale data (Perianes-Rodriguez et al., 2016). Using bibliometric methods, VC literatures can be visually analyzed, and the research results of the past decade can be displayed from multiple dimensions, laying the foundation for the in-depth development and research of VC worldwide. Although numerous studies have been conducted in the field of VC, no bibliometric research has examined VC to date. Therefore, we aimed to select the Web of Science Core Collection (WoSCC) database as a data source using CiteSpace, VOSviewer, and Microsoft Excel to display the knowledge base, developmental trends, and emerging hotspots of VC research.

Materials and Methods

Search Strategy

Relevant literatures were obtained from the SCI-E database of the WoSCC on February 1, 2021. The search formula was “TS = (vascular calcification OR arterial calcification OR aortic calcification OR vascular smooth muscle cell mineralization OR vascular smooth muscle cell calcification).” The search results were confined by language (English), literature type (article), and publication year (2011–2020). Ultimately, 8,238 records were identified.

Data Analysis

CiteSpace 5.7. R4, VOSviewer 1.6.16, and Microsoft Excel 2019 were used to analyze and visualize the literature on VC research.

The visualization map created by CiteSpace consists of nodes and lines. The nodes in the graph represent the node types, such as country, institution, author, keyword, and reference. The size of each node stands for the frequency, and the connections between nodes represent cooperation, co-occurrence, or co-citation relationships. Node size is proportional to its frequency by type. The number of lines represents the degree of the connection between the nodes. Betweenness centrality is applied to quantify the importance of a node’s position in the network. The higher the betweenness centrality, the greater the number of connections in the network passing through the node. Nodes with a betweenness centrality greater than 0.1 are often marked with purple circles (Zheng and Wang, 2019). In our study, countries, institutions, and co-cited references were selected as nodes for the visualization analysis. Burst keywords were also detected using CiteSpace. The basic parameters were as follows: time slicing (2011–2020), years per slice (1), top N per slice (50), pruning (pathfinder and pruning sliced networks), and visualization (cluster view-static and show merged network).

VOSviewer can be used to construct a scientific knowledge network and display the structure, evolution, and cooperation of the research field (Van Eck and Waltman, 2010). In this study, VOSviewer was applied to visually analyze co-authorship, co-cited journals, and keyword co-occurrence as well as construct the density maps.

Microsoft Excel was used to construct the tables and demonstrate the annual national trends in publications and citations.

Results

Temporal Trends of Publications and Citations

A total of 8,238 English articles related to VC were included. There were 135,220 and 16.41 total and mean citations, respectively. The H-index count was 117. The H-index represents H papers published by the journal/author/country, each of which was cited at least H times. It can be used to evaluate the scientific impact of the journal, author, or country.

From 2011 to 2020, the publications in the VC field generally showed an upward trend except for a slight decline in 2014 and 2018 (Figure 1A). A total of 1985 articles were published from 2019 to 2020, a high-yield and rapid growth stage in this field. As shown in Figure 1A, the annual number of citations were increased sharply in the past decade, especially from 2018 to 2020. The linear fitting of VC-related articles showed a significant correlation (R2 = 0.9949) between the year and the citations. The above results demonstrate that VC has received widespread attention from global scholars and that extensive research was conducted recently.

FIGURE 1.

FIGURE 1

Open in a new tab

Trends in publications and citations of vascular calcification research. (A) The annual trends of global publications and citations. (B) The temporal trends of publications from the top 10 countries. (C) H-index, average citations (citations per article), and total citations of the top 10 countries.

Distribution of Countries and Institutions

All literatures were distributed among 104 countries and 7,677 institutions. The United States had the most publications, with 2,555 (31.01%) articles, followed by China [1,128 (13.69%)], Germany [781 (9.48%)], Japan [729 (8.85%)], and Italy [536 (6.51%)] (Table 1). As shown in Figure 2A, the nodes of the United States, Germany, France, Canada, Spain, Italy, and England are marked with a purple circle, representing close cooperation with each other. The annual national publications (Figure 1B) and citations (Figure 1C) of the top 10 productive countries were further identified. The overall trend of annual publications by these countries exhibited a steady growth from 2011 to 2018 and a sharp increase beginning in 2019. In terms of mean citations, the top three countries were England (34.45), Canada (33.59), and Germany (32.57). The United States (99), Germany (66), and England (60) were the top three countries with a high H-index. The above results indicate that the United States, Germany, England, and Canada have great influence in the field of VC research.

TABLE 1.

Top 10 countries by publications, citations and centrality.

Rank Country Publications % of 8,238 Total Citations Average Citations H-index Rank Country Centrality
1 United States 2,555 31.01 61,994 24.26 99 1 United States 0.28
2 China 1,128 13.69 11,146 9.88 42 2 Germany 0.24
3 Germany 781 9.48 19,570 25.06 66 3 France 0.15
4 Japan 729 8.85 9,205 12.63 42 4 Canada 0.15
5 Italy 536 6.51 10,597 19.77 46 5 Spain 0.14
6 England 504 6.12 17,361 34.45 60 6 Italy 0.12
7 Netherlands 489 5.94 12,171 24.89 56 7 England 0.12
8 France 416 5.05 10,314 24.79 49 8 Netherlands 0.06
9 Canada 408 4.95 13,706 33.59 52 9 Switzerland 0.06
10 Korea 373 4.53 4,450 11.93 31 10 Turkey 0.05
Open in a new tab

FIGURE 2.

FIGURE 2

Open in a new tab

CiteSpace visualization map of countries and institutions involved in vascular calcification research. (A) Collaboration network of countries. N = 104, E = 798. N represents the number of network nodes. E represents the number of connections. (B) Collaboration network of institutions. N = 480, E = 3,382.

As shown in Table 2, the University of California System [367 publications (4.45%)], Harvard University [350 publications (4.25%)], and the National Institute of Health Care [246 publications (2.99%)] were the main research forces in this field. The centrality of Hopkins University and Brigham and Women’s Hospital was more than 0.1, indicating that these institutions were the key hubs for promoting international cooperation between relevant research institutions (Figure 2B). Among top ten institutions, most of them are American institutions (Table 2), suggesting that the United States is the leading driving force, and still dominates in this research field.

TABLE 2.

Top 10 institutions distributed by publications and centrality.

Rank Institution Publications Original Country Institution Centrality Original Country
1 Univ Calif System 367 United States Johns Hopkins univ 0.11 United States
2 Univ Harvard 350 United States Brigham and Women’s Hosp 0.11 United States
3 INSERM 246 France Univ Calif San Diego 0.08 United States
4 Univ Calif Los Angeles 189 United States Karolinska inst 0.08 Sweden
5 Univ London 167 England Emory univ 0.07 United States
6 Brigham and Women’s Hosp 155 United States Univ Penn 0.06 United States
7 Johns Hopkins univ 154 United States Univ Coll London 0.06 England
8 US department VA 153 United States NSERM 0.06 France
9 Univ Washington 151 United States Univ Leiden 0.06 Netherlands
10 Univ Seattle 149 United States Univ Washington 0.05 United States
Open in a new tab

Distribution of Authors and Co-Cited Authors

A total of 37,697 authors contributed to VC research. Budoff MJ, the most productive author from the United States, published 68 articles, followed by Wang Y (63), De Jone PA (54), and Massy ZA (53). The top three most published authors were Floege J (2,452), Pibarot P (2,302), and Budoff MJ (2,280). The above authors’ institution distribution showed that most institutions originated from North America and Europe (Table 3). As shown in Figure 3A, Budoff MJ cooperated closely with Criqui MH, Blumenthal RS, and Blaha MJ. In addition, Floege J collaborated frequently with Block GA, Raggi P, and Ketteler M. As shown in Figure 3B, London GM had the highest co-citations, followed by Block GA and Moe SM, and all of their co-citations exceeded 800. The above analysis suggests that they have a strong academic reputation in this area.

TABLE 3.

Top 10 authors distributed by publications and citations.

Rank Author Publications Country Institution Cited author Total Citations Average Citations H-index Country Institution
1 Budoff MJ 68 United States Univ Washington Floege J 2,452 66.27 21 Germany Rhein Westfal TH Aachen
2 Wang Y 63 China Cent S univ Pibarot P 2,302 50.04 25 Canada Univ Laval
3 DE Jong PA 54 Netherlands Uuniv med CTR utrecht Budoff MJ 2,280 32.47 22 United States Univ Washington
4 Massy ZA 53 France Amiens univ Hosp Dweck MR 2,151 52.46 21 Scotland Univ Edinburgh
5 Vermeer C 49 Netherlands Maastricht univ Newby DE 2,056 55.57 20 Scotland Univ Edinburgh
6 Pibarot P 46 Canada Univ Laval Vermeer C 1,996 39.92 27 Netherlands Maastricht univ
7 Dweck MR 41 Scotland Univ edinburgh Schurgers LJ 1,817 49.11 22 Netherlands Maastricht univ
8 Liu Y 39 China Harbin med univ Shanahan CM 1,798 74.92 19 England Kjings Coll London
9 Wang L 38 China Peking univ Massy ZA 1,757 33.15 28 France Amiens univ Hosp
10 Floege J 37 Germany Rhein westfal TH Aachen Aakawa E 1,621 45.03 23 United States Harvard med Sch
Open in a new tab

FIGURE 3.

FIGURE 3

Open in a new tab

VOSviewer visualization map of authors and co-cited authors devoted to vascular calcification research. (A) Cooperation network of authors. Of the 42,046 authors, 113 had published at least 15 documents. (B) Co-citation network of authors. Of the 90,638 co-cited authors, 254 had at least 100 citations.

Distribution of Journals

All articles were published in 1,476 journals, including 19 with more than 50 articles. The impact factor (IF) and journal quartile were obtained from Journal Citation Reports 2019. The top three prolific journals were PLOS ONE (IF2.74), Atherosclerosis (IF3.919), and Arteriosclerosis Thrombosis and Vascular Biology (IF6.604). In addition, the Journal of the American College of Cardiology (IF20.589) had the greatest number of citations, followed by Arteriosclerosis Thrombosis and Vascular Biology (IF6.604) and PLOS ONE (IF2.74) (Table 4). The top three co-cited journals were Circulation (IF23.609), Journal of the American College of Cardiology (IF20.589), and Kidney International (IF8.52) (Figures 4A,B). Most journals listed in Table 4 were classified in Q1 or Q2, and these results indicate that the above journals have strong academic performance in the field of VC research.

TABLE 4.

Top 10 journals distributed by publications and citations.

Rank Journal Publications % of 8,238 IF(JCR 2019) JIF quartile Journal Total Citations Average Citations H-index IF(JCR 2019) JCR quartile
1 Plos one 283 3.44 2.74 Q2 J Am Coll Cardiol 6,907 71.21 45 20.589 Q1
2 Atherosclerosis 196 2.38 3.919 Q2 Arterioscl throm Vas 5,423 35.68 41 6.604 Q1
3 Arterioscl Throm Vas 152 1.85 6.604 Q1 Plos one 4,699 16.6 36 2.74 Q2
4 Nephrol Dial transpl 126 1.53 4.531 Q1 Nephrol Dial transpl 3,746 29.04 35 4.531 Q1
5 Sci Rep-UK 111 1.35 3.998 Q1 Circ res 3,641 98.41 28 14.467 Q1
6 Catheter Cardio inte 100 1.21 2.044 Q2 Kidney int 3,446 54.7 33 8.945 Q1
7 Int J Cardiol 92 1.12 3.229 Q2 New engl J med 3,355 671 5 74.699 Q1
8 BMC Nephrol 78 0.95 1.913 Q3 Atherosclerosis 3,308 16.88 32 3.919 Q2
9 J Am Coll Cardiol 77 0.93 4.605 Q1 Circulation 3,039 70.67 28 23.603 Q1
10 Am J Cardiol 75 0.91 2.57 Q2 J Am Soc Nephrol 2,748 80.82 25 9.274 Q1
Open in a new tab

FIGURE 4.

FIGURE 4

Open in a new tab

VOSviewer visualization map of most commonly cited journals related to vascular calcification research. (A) Co-citation network of journals. Of the 12,149 most commonly cited journals, 99 had published at least 500 studies. (B) The density map of the most commonly cited journals. The dark blue nodes represent journals with large numbers of citations.

Analysis of Highly Cited Articles and Co-Cited References

As shown in Table 5, the top three cited articles were as follows. 1) “Two-year outcomes after transcatheter or surgical aortic-valve replacement” by Kodali SK in 2012 (1,573 citations). This study conducted a 2-years follow-up of patients with aortic valve stenosis or calcification in the PARTNER trial. These results support transcatheter aortic valve replacement as an appropriate alternative to surgical treatment for high-risk patients, but paravalvular regurgitation occurred more frequently after transcatheter aortic valve replacement (Kodali et al., 2012). 2) “Mechanisms of plaque formation and rupture” by Bentzon JF in 2014 (664 citations). This article discussed the mechanism of the initiation and development of atherosclerotic plaques, the sudden deposition of life-threatening thrombi, and the concepts of plaque burden, mobility, and vulnerability (Bentzon et al., 2014). 3) “Klotho deficiency causes vascular calcification in chronic kidney disease” by Hu MC in 2011 (551 citations). The study reported that Klotho improved vascular calcification by enhancing the excretion of phosphate in the urine, maintaining glomerular filtration, and directly inhibiting the absorption of phosphate by vascular smooth muscle. Therefore, a Klotho deficiency can lead to the development of VC (Hu et al., 2011). Notably, the number of citations does not fully reflect the quality of the article, because the citations of articles published earlier are generally higher than those of the latest articles. We have to consider the influence of time as a confounding factor on citation analysis.

TABLE 5.

Top 10 cited literatures.

Rank Citations Author Title Source Year Column Page DOI
1 1,573 Kodali SK Two-year outcomes after transcatheter or surgical aortic-valve replacement New engl J med 2012 366 1,686 10.1056/NEJMoa1200384
2 664 Bentzon JF Mechanisms of plaque formation and rupture Circ res 2014 114 1852 10.1161/CIRCRESAHA.114.302721
3 551 Hu MC Klotho deficiency Causes Vascular Calcification in chronic kidney disease J Am Coll Cardiol 2011 22 124 10.1681/ASN.2009121311
4 542 Chertow GM Effect of Cinacalcet on cardiovascular disease in patients undergoing dialysis New engl J med 2012 367 2,482 10.1056/NEJMoa1205624
5 493 Joshi NV F-18-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a Prospective clinical trial Lancet 2014 383 705 10.1016/S0140-6736(13)61754-7
6 474 Shanahan CM Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate Circ res 2011 109 697 10.1161/CIRCRESAHA.110.234914
7 434 Thanassoulis G Genetic associations with Valvular Calcification and Aortic Stenosis New engl J med 2013 368 503 10.1056/NEJMoa1109034
8 328 Block GA Effects of phosphate binders in moderate CKD J Am Soc Nephrol 2012 23 1,407 10.1681/ASN.2012030223
9 325 Raggi P The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis Nephrol Dial transpl 2011 26 1,327 10.1093/ndt/gfq725
10 323 Hayashida K Transfemoral aortic valve implantation new criteria to predict vascular complications JACC-cardiovasc inte 2011 4 851 10.1016/j.jcin 2011.03.019
Open in a new tab

As shown in Figure 5A, “Shanahan CM (2011),” “Lanzer P (2014),” “Sage AP (2010),” and CKD-MBD Work Group (2009)” were frequently co-cited references. A cluster analysis showed that the high-frequency terms related to VC research were mainly clustered into 18 categories (Figure 5B). The top five clusters were “calciprotein particles,” “transcatheter aortic valve replacement,” “calcified aortic valve disease,” and “fibroblast growth factor 23,” “vascular smooth muscle cells” and “atherosclerosis” (Table 6). The silhouette (S) value refers to the average contour value of the cluster. It is generally considered that, with an s > 0.5, the cluster is reasonable, while with an s > 0.7, the cluster is convincing (Chen et al., 2012). In our study, all of the silhouette values of the top 10 clusters were above 0.7, which indicated that the clusters were convincing. “calciprotein particles” (Cluster ID 0#) was the largest cluster with 125 references, and literatures related to calciprotein particles could be currently primary hotspots.

FIGURE 5.

FIGURE 5

Open in a new tab

Analysis of most commonly cited references related to vascular calcification research. (A) Co-citation network of references. (B) Timeline view of most commonly co-cited references.

TABLE 6.

Top 10 largest clusters of co-cited references.

Cluster ID Top terms Size S-value Mean (year)
#0 Calciprotein particles 125 0.829 2016
#1 Transcatheter aortic valve replacement 116 0.977 2013
#2 Calcific aortic valve disease 103 0.933 2011
#3 Fibroblast growth factor 23 96 0.908 2010
#4 Vascular smooth muscle cells 81 0.886 2009
#5 Atherosclerosis 75 0.903 2013
#6 Pyrophosphate 64 0.897 2011
#7 Vitamin d 63 0.918 2007
#8 Vitamin k 58 0.919 2009
#9 Sclerostin 44 0.849 2013
Open in a new tab

Analysis of Keywords

As shown in Table 7, the keywords used at high frequency were: “vascular calcification,” “calcification,” “atherosclerosis,” “chronic kidney disease,” and “mortality”. Keywords with high centrality were: “vascular calcification,” “chronic kidney disease,” “computed tomography,” “cardiovascular disease,” and “atherosclerosis”. As shown in Figure 6A, the yellow cluster was constituted mainly of “vascular calcification,” “chronic kidney disease,” “calcium,” “coronary artery calcification,” and “mortality”. The cluster mainly explored the mechanisms and pathogenesis of VC in patients with CKD or on dialysis. The blue cluster focused on “atherosclerosis,” “cardiovascular disease,” “risk-factors,” “progression,” “arterial stiffness” and “cardiovascular events”. It primarily probed various pathophysiological changes associated with cardiovascular disease, including atherosclerosis, arterial calcification, and arterial stiffness. Furthermore, the association between VC progression and the incidence of cardiovascular adverse events was also investigated. In addition, “stenosis,” “computed tomography,” “replacement,” “implantation” and “outcomes” were chief components of the red cluster. This study compared the therapeutic effects of open valve replacement and transcatheter valve replacement for aortic valve or heart valve stenosis. Moreover, the green cluster primarily consisted of “calcification,” “inflammation,” “expression,” “mechanisms” and “smooth muscle cell”. In this cluster, a series of in vitro experiments was performed to describe the molecular mechanism of VC. According to the density map of keywords, “vascular calcification,” “chronic kidney disease,” “hemodialysis,” “coronary artery calcification,” “mortality,” “vascular smooth muscle cells,” and “expression” had higher weight (Figure 6B).

TABLE 7.

Top 10 keywords by frequency and centrality.

Rank Frequency Keyword Centrality Keyword
1 2,170 Vascular calcification 0.54 Vascular calcification
2 2,117 Calcification 0.31 Chronic kidney disease
3 1,437 Atherosclerosis 0.28 Computed tomography
4 1,240 Chronic kidney disease 0.22 Cardiovascular disease
5 981 Mortality 0.18 Atherosclerosis
6 928 Cardiovascular disease 0.18 Stenosis
7 715 Calcium 0.17 Calcification
8 710 Expression 0.15 Expression
9 676 Inflammation 0.13 Smooth muscle cell
10 632 Stenosis 0.12 Stage renal disease
Open in a new tab

FIGURE 6.

FIGURE 6

Open in a new tab

Analysis of all keywords in studies related to vascular calcification research. (A) VOSviewer visualization map of co-occurring keywords. Of the 18,983 keywords, 133 had at least 100 co-occurrences. (B) The density map of keywords. The closer the keyword node color is to red, the higher the frequency of its co-occurrence.

Burst keywords can reflect emerging academic trends and new topics, predict the Frontier research direction, and explore potential hotspots in a field. As shown in Table 8, the keywords were closely concentrated between 2017 and 2020. Furthermore, the burst keywords in this period mainly included “revascularization,” “microRNA,” “microcalcification,” “matrix vesicle” and “calciprotein particles”. Burst detection can be divided into two aspects: the first is closely related to revascularization of coronary atherosclerosis and heart valve stenosis, while the second chiefly focused on the molecular mechanism and relevant treatment of VC.

TABLE 8.

Top 8 keywords with strongest citation burst.

Keyword Strength Begin End 2011–2020
Atherosclerosis mesa 6.93 2014 2017 ▂▂▂▃▃▃▃▂▂▂
Paravalvular regurgitation 9.87 2016 2018 ▂▂▂▂▂▃▃▃▂▂
TNF-α 6.79 2016 2017 ▂▂▂▂▂▃▃▂▂▂
Revascularization 8.9 2017 2020 ▂▂▂▂▂▂▃▃▃▃
Microrna 7.45 2017 2020 ▂▂▂▂▂▂▃▃▃▃
Microcalcification 7.41 2017 2020 ▂▂▂▂▂▂▃▃▃▃
Matrix vesicle 7.41 2017 2020 ▂▂▂▂▂▂▃▃▃▃
Calciprotein particle 6.76 2018 2020 ▂▂▂▂▂▂▂▃▃▃
Open in a new tab

Discussion

General Information

In the present study, we utilized bibliometric technology to analyze literature related to VC. Our results indicated that the annual publications and citations of VC have shown a significant growth trend in recent years. As the main driving force, the United States had the highest number of publications and total citations. Furthermore, eight of the top 10 prolific institutions were from the United States, such as the University of California System and Harvard University. In addition, close cooperation was observed between American institutions, which maximized its geographical advantages and further strengthened its academic influence on VC research. Although England ranked sixth in the number of publications, it had the highest mean number of citations, suggesting very high quality of its publications. Moreover, the University of London in England had a high number of publications and collaborated closely with other institutions. The above results showed that European and North American institutions were dominant in the VC research direction, whereas China had no leading institutions in this field.

Additionally, our results demonstrated that Budoff MJ was the most productive author with a high number of citations. He mainly focused on imaging and made significant contributions to the identification of VC lesions. He also participated in various sub-studies of multi-ethnic research on atherosclerosis. These studies mainly focused on the impact of valve calcification and coronary atherosclerosis on the incidence and mortality of patients with CVD (Budoff et al., 2011). He also explored the association between VC progression and patient prognosis (Fashanu et al., 2020). We also found that the most commonly cited author was Floege J from Germany. He mainly studied the occurrence and development of VC in patients with CKD under certain pathological conditions. These pathological states include secondary hyperparathyroidism, hypermagnesemia, anticoagulant drugs, and vitamin K deficiency (Floege, 2015; Floege, 2018). Moreover, the author with the highest number of co-citations was London GM, who mainly studied arterial aging, stiffness changes, and vascular remodeling in CKD patients (London et al., 2016; London, 2018). The above authors have high academic reputations in VC research and have contributed significantly to developments and advancements in this field.

Journal Citation Reports 2019 was used to obtain the impact factor (IF) and quartile (Q) of a journal category (Chen L. et al., 2020). The Journal Citation Reports division divides the journals in the same discipline into four equal parts, with the top 25% being Q1 and 25–50% being Q2. We found that most of the productive journals were classified as Q1 or Q2, and Arteriosclerosis Thrombosis and Vascular Biology (IF6.604, Q1) had the highest IF. Although PLOS ONE (IF2.74, Q2) and Atherosclerosis (IF3.919, Q2) were the top two productive journals, their IF values were less than 5. This indicates that improving research quality while increasing output may contribute to enhancing their academic influence. Among the most commonly cited journals, the New England Journal of Medicine (IF74.699, Q1), Circulation (IF23.603, Q1), and Journal of the American College of Cardiology (IF20.589, Q1) had IF values higher than 20. This suggests that the three aforementioned journals published high-quality research with convincing and mature outcomes.

Hotspots and Frontiers

Through the potent combination of top keywords and literature, we attribute the research hotspots as follows: 1) The mechanism of VC in CKD or dialysis patients, including inflammation (Yuan et al., 2020), VSMC phenotype of osteogenic differentiation (Yang et al., 2020), overexpression of calcification-promoting factors (oxidative stress) (Watanabe et al., 2020), parathyroid hormone (Imafuku et al., 2020), fibroblast growth factor 23 (Jiang et al., 2020) as well as the suppression of calcification inhibitors (Liu et al., 2018); 2) various pathophysiological changes (atherosclerosis, arterial calcification, arterial stiffness, etc.) accompanied by CVD, and the impact of these changes on the prognosis of patients (Stabley and Towler, 2017; Mszar et al., 2020); 3) comparison of therapeutic effects between open valve replacement surgery and minimally invasive transcatheter valve replacement for aortic valve or heart valve stenosis (Ielasi et al., 2021); and 4) molecular and cellular mechanisms of VC, including various molecular signaling pathways (Chen W.-J. et al., 2020) and abnormal proliferation (Miyata et al., 2020) or apoptosis (Boraldi et al., 2021) of cells that regulate VC.

Based on the analysis of burst keywords, we speculated that endovascular intervention measures for VC will become an emerging academic trend in VC research. These measures included minimally invasive transcatheter valve replacement for aortic valve or heart valve stenosis (Ielasi et al., 2021), percutaneous coronary intervention for coronary artery calcification (Jia et al., 2020), and intravascular lithotripsy (Dini et al., 2019) for peripheral arterial disease. Concurrently, signal transduction pathways have been found to play a significant role in VC occurrence and progression. Therefore, research on functional pathways has always been favored by researchers and will never become outdated. Recent popular pathways include the miR-126-3p-DKK1/LRP6 pathway (Zeng et al., 2021), NR4A1/DNA-PKcs/p53 pathway (Zhu et al., 2020), AMPK/OPA1 pathway (Chen W. R. et al., 2020), and Keap1/Nrf2 pathway (Cui et al., 2020). Extensive Researches on signal transduction pathways could provide novel strategies for the development of new drugs targeting VC. The field of ncRNAs has recently emerged as a focus of VC research and has received widespread attention from scholars worldwide. Accumulating evidence demonstrates that ncRNAs, including circular RNAs (Ryu et al., 2020), microRNAs (Chao et al., 2020), and long ncRNAs (Ryu et al., 2021), can modulate VC by acting as promoters or inhibitors and may play critical role in the prevention, diagnosis, and treatment.

Limitations

To date, this study is the first bibliometric analysis of hotspots and dynamic frontiers of VC research in the past decade. In addition, three tools were applied to perform the survey simultaneously, enabling our research results to be more accurate and objective. However, the present study has some limitations. First, all data were extracted only from the WoSCC, and we did not search more databases, such as Google Scholar or PubMed. However, the WoSCC is an authoritative, comprehensive, and multidisciplinary core journal citation index database. Second, only English articles were included, which may have decreased the number of retrieved articles. And finally, the amount of literature related to VC is huge. With the rapid updating of hot topics and research frontiers of VC, we may have missed some research hotspots.

Conclusion

Extensive studies related to VC have been conducted in the past decade, and the number of retrieved articles demonstrated an obvious growth trend, especially from 2019 to 2020. The most productive country, institution, journal, and author are the United States, the University of California System, PLOS ONE, and Budoff MJ, respectively. The most commonly cited country, journal, and author are the United States, Journal of the American College of Cardiology, and Floege J, respectively. The document with the highest number of citations is “Two-year outcomes after transcatheter or surgical aortic valve replacement” by Kodali SK in 2012. The main research foci in the VC field are the molecular mechanism of VC and the prognosis of VC in patients with CKD or cardiovascular disease. In addition, endovascular therapy and the development of new drugs targeting signal pathways for VC will become the foci of future research. Moreover, ncRNAs related to the diagnosis and treatment of VC have great research potential. In general, this study systematically analyzed the literatures on VC and reported the research results of the past decade in multiple dimensions, which can lay the foundation for the in-depth development and research of VC worldwide. Our results revealed the authors and institutions that can cooperate and provide reference for future research directions and scientific decision-making.

Acknowledgments

We really appreciate for the guest editors’ inspiration and continuous support on this research.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author Contributions

QD and QL designed the study. YC and JL collected and verified the data. QD and QL performed software analysis. QD and QL drafted the first vision. LL, XH, and QZ revised and approved the final version of the manuscript.

Funding

This research is supported by the National Natural Science Foundation of China (81870190).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Bäck M., Aranyi T., Cancela M. L., Carracedo M., Conceição N., Leftheriotis G., et al. (2019). Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement from the COST Action EuroSoftCalcNet. Front. Cardiovasc. Med. 5, 196. 10.3389/fcvm.2018.00196 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bentzon J. F., Otsuka F., Virmani R., Falk E. (2014). Mechanisms of Plaque Formation and Rupture. Circ. Res. 114 (12), 1852–1866. 10.1161/CIRCRESAHA.114.302721 [DOI] [PubMed] [Google Scholar]
  3. Boraldi F., Lofaro F. D., Quaglino D. (2021). Apoptosis in the Extraosseous Calcification Process. Cells 10 (1), 131. 10.3390/cells10010131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Budoff M. J., Nasir K., Katz R., Takasu J., Carr J. J., Wong N. D., et al. (2011). Thoracic Aortic Calcification and Coronary Heart Disease Events: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 215 (1), 196–202. 10.1016/j.atherosclerosis.2010.11.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chao C.-T., Yeh H.-Y., Tsai Y.-T., Chiang C.-K., Chen H.-W. (2020). A Combined microRNA and Target Protein-Based Panel for Predicting the Probability and Severity of Uraemic Vascular Calcification: a Translational Study. Cardiovasc. Res. 31, cvaa255. 10.1093/cvr/cvaa255 [DOI] [PubMed] [Google Scholar]
  6. Chen C. (2006). CiteSpace II: Detecting and Visualizing Emerging Trends and Transient Patterns in Scientific Literature. J. Am. Soc. Inf. Sci. 57 (3), 359–377. 10.1002/asi.20317 [DOI] [Google Scholar]
  7. Chen C., Hu Z., Liu S., Tseng H. (2012). Emerging Trends in Regenerative Medicine: a Scientometric Analysis inCiteSpace. Expert Opin. Biol. Ther. 12 (5), 593–608. 10.1517/14712598.2012.674507 [DOI] [PubMed] [Google Scholar]
  8. Chen L., Ma S., Hu D., Lin H., Zhu Y., Chen K., et al. (2020). Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research. Front. Pharmacol. 11 (11), 561494. 10.3389/fphar.2020.561494 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen W.-J., Lai Y.-J., Lee J.-L., Wu S.-T., Hsu Y.-J. (2020). CREB/ATF3 Signaling Mediates Indoxyl Sulfate-Induced Vascular Smooth Muscle Cell Proliferation and Neointimal Formation in Uremia. Atherosclerosis 315, 43–54. 10.1016/j.atherosclerosis.2020.11.009 [DOI] [PubMed] [Google Scholar]
  10. Chen W. R., Zhou Y. J., Yang J. Q., Liu F., Wu X. P., Sha Y. (2020). Melatonin Attenuates Calcium Deposition from Vascular Smooth Muscle Cells by Activating Mitochondrial Fusion and Mitophagy via an AMPK/OPA1 Signaling Pathway. Oxidative Med. Cell Longevity 2020, 1–23. 10.1155/2020/5298483 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cui L., Zhou Q., Zheng X., Sun B., Zhao S. (2020). Mitoquinone Attenuates Vascular Calcification by Suppressing Oxidative Stress and Reducing Apoptosis of Vascular Smooth Muscle Cells via the Keap1/Nrf2 Pathway. Free Radic. Biol. Med. 161, 23–31. 10.1016/j.freeradbiomed.2020.09.028 [DOI] [PubMed] [Google Scholar]
  12. Dini C. S., Tomberli B., Mattesini A., Ristalli F., Valente S., Stolcova M., et al. (2019). Intravascular Lithotripsy for Calcific Coronary and Peripheral Artery Stenoses. EuroIntervention 15 (8), 714–721. 10.4244/EIJ-D-18-01056 [DOI] [PubMed] [Google Scholar]
  13. Dong Q., Chen Y., Liu W., Liu X., Chen A., Yang X., et al. (2020). 25-Hydroxycholesterol Promotes Vascular Calcification via Activation of Endoplasmic Reticulum Stress. Eur. J. Pharmacol. 880, 173165. 10.1016/j.ejphar.2020.173165 [DOI] [PubMed] [Google Scholar]
  14. Fashanu O. E., Bizanti A., Al-Abdouh A., Zhao D., Budoff M. J., Thomas I. C., et al. (2020). Progression of Valvular Calcification and Risk of Incident Stroke: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 307, 32–38. 10.1016/j.atherosclerosis.2020.06.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Floege J. (2018). Magnesium Concentration in Dialysate. Cjasn 13 (9), 1309–1310. 10.2215/CJN.08380718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Floege J. (2015). Magnesium in CKD: More Than a Calcification Inhibitor? J. Nephrol. 28 (3), 269–277. 10.1007/s40620-014-0140-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gourgas O., Marulanda J., Zhang P., Murshed M., Cerruti M. (2018). Multidisciplinary Approach to Understand Medial Arterial Calcification. Atvb 38 (2), 363–372. 10.1161/ATVBAHA.117.309808 [DOI] [PubMed] [Google Scholar]
  18. Hu M. C., Shi M., Zhang J., Quiñones H., Griffith C., Kuro-o M., et al. (2011). Klotho Deficiency Causes Vascular Calcification in Chronic Kidney Disease. Jasn 22 (1), 124–136. 10.1681/ASN.2009121311 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ielasi A., Moscarella E., Mangieri A., Giannini F., Tchetchè D., Kim W.-K., et al. (2021). Procedural and Clinical Outcomes of Type 0 versus Type 1 Bicuspid Aortic Valve Stenosis Undergoing Trans-catheter Valve Replacement with New Generation Devices: Insight from the BEAT International Collaborative Registry. Int. J. Cardiol. 325, 109–114. 10.1016/j.ijcard.2020.10.050 [DOI] [PubMed] [Google Scholar]
  20. Imafuku T., Tanaka M., Tokunaga K., Miyamura S., Kato H., Tanaka S., et al. (2020). Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis. Biol. Pharm. Bull. 43 (10), 1583–1590. 10.1248/bpb.b20-00472 [DOI] [PubMed] [Google Scholar]
  21. Jia S., Li J., Zhang C., Liu Y., Yuan D., Xu N., et al. (2020). Long-Term Prognosis of Moderate to Severe Coronary Artery Calcification in Patients Undergoing Percutaneous Coronary Intervention. Circ. J. 85 (1), 50–58. 10.1253/circj.CJ-20-0761 [DOI] [PubMed] [Google Scholar]
  22. Jiang J., Li Y., Zheng D., Wang Z., Zhou H., Liu G. (2020). Fortified Phosphorus-lowering T-reatment through A-dministration of L-anthanum P-rotects against V-ascular C-alcification via R-egulation of FGF23 in C-hronic K-idney D-isease. Int. J. Mol. Med. 46 (5), 1783–1793. 10.3892/ijmm.2020.4719 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kodali S. K., Williams M. R., Smith C. R., Svensson L. G., Webb J. G., Makkar R. R., et al. (2012). Two-year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement. N. Engl. J. Med. 366 (18), 1686–1695. 10.1056/NEJMoa1200384 [DOI] [PubMed] [Google Scholar]
  24. Kong Y., Liang Q., Chen Y., Yang P., Liu X., Li Y., et al. (2018). Hyaluronan Negatively Regulates Vascular Calcification Involving BMP2 Signaling. Lab. Invest. 98 (10), 1320–1332. 10.1038/s41374-018-0076-x [DOI] [PubMed] [Google Scholar]
  25. Lee S. J., Lee I.-K., Jeon J.-H. (2020). Vascular Calcification-New Insights into its Mechanism. Ijms 21 (8), 2685. 10.3390/ijms21082685 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Li Z., Wu J., Zhang X., Ou C., Zhong X., Chen Y., et al. (2019). CDC42 Promotes Vascular Calcification in Chronic Kidney Disease. J. Pathol. 249 (4), 461–471. 10.1002/path.5334 [DOI] [PubMed] [Google Scholar]
  27. Liu L., Zeng P., Yang X., Duan Y., Zhang W., Ma C., et al. (2018). Inhibition of Vascular Calcification. Atvb 38 (10), 2382–2395. 10.1161/ATVBAHA.118.311546 [DOI] [PubMed] [Google Scholar]
  28. London G. M. (2018). Arterial Stiffness in Chronic Kidney Disease and End-Stage Renal Disease. Blood Purif. 45 (1-3), 154–158. 10.1159/000485146 [DOI] [PubMed] [Google Scholar]
  29. London G. M., Safar M. E., Pannier B. (2016). Aortic Aging in ESRD: Structural, Hemodynamic, and Mortality Implications. Jasn 27 (6), 1837–1846. 10.1681/ASN.2015060617 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Miyata T., Minami M., Kataoka H., Hayashi K., Ikedo T., Yang T., et al. (2020). Osteoprotegerin Prevents Intracranial Aneurysm Progression by Promoting Collagen Biosynthesis and Vascular Smooth Muscle Cell Proliferation. Jaha 9 (17), e015731. 10.1161/JAHA.119.015731 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Mszar R., Nasir K., Santos R. D. (2020). Coronary Artery Calcification in Familial Hypercholesterolemia. Circulation 142 (15), 1405–1407. 10.1161/CIRCULATIONAHA.120.049057 [DOI] [PubMed] [Google Scholar]
  32. Neutel C. H. G., Hendrickx J. O., Martinet W., De Meyer G. R. Y., Guns P.-J. (2020). The Protective Effects of the Autophagic and Lysosomal Machinery in Vascular and Valvular Calcification: A Systematic Review. Ijms 21 (23), 8933. 10.3390/ijms21238933 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Park S., Hong M., Lee H., Cho N.-j., Lee E.-Y., Lee W.-Y., et al. (2021). New Model for Predicting the Presence of Coronary Artery Calcification. Jcm 10 (3), 457. 10.3390/jcm10030457 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Perelló J., Ferrer M. D., Pérez M., Kaesler N., Brandenburg V. M., Behets G. J., et al. (2020). Mechanism of Action of SNF472, a Novel Calcification Inhibitor to Treat Vascular Calcification and Calciphylaxis. Br. J. Pharmacol. 177 (19), 4400–4415. 10.1111/bph.15163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Perianes-Rodriguez A., Waltman L., Van Eck N. J. (2016). Constructing Bibliometric Networks: A Comparison between Full and Fractional Counting. J. Informetrics 10 (4), 1178–1195. 10.1016/j.joi.2016.10.006 [DOI] [Google Scholar]
  36. Poterucha T. J., Goldhaber S. Z. (2016). Warfarin and Vascular Calcification. Am. J. Med. 129 (6), e1.635–4. 10.1016/j.amjmed.2015.11.032 [DOI] [PubMed] [Google Scholar]
  37. Rattazzi M., Bennett B. J., Bea F., Kirk E. A., Ricks J. L., Speer M., et al. (2005). Calcification of Advanced Atherosclerotic Lesions in the Innominate Arteries of ApoE-Deficient Mice. Atvb 25 (7), 1420–1425. 10.1161/01.ATV.0000166600.58468.1b [DOI] [PubMed] [Google Scholar]
  38. Ryu J., Ahn Y., Kook H., Kim Y.-K. (2021). The Roles of Non-coding RNAs in Vascular Calcification and Opportunities as Therapeutic Targets. Pharmacol. Ther. 218, 107675. 10.1016/j.pharmthera.2020.107675 [DOI] [PubMed] [Google Scholar]
  39. Ryu J., Kwon D.-H., Choe N., Shin S., Jeong G., Lim Y.-H., et al. (2020). Characterization of Circular RNAs in Vascular Smooth Muscle Cells with Vascular Calcification. Mol. Ther. - Nucleic Acids 19, 31–41. 10.1016/j.omtn.2019.11.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Shao J.-S., Cheng S.-L., Sadhu J., Towler D. A. (2010). Inflammation and the Osteogenic Regulation of Vascular Calcification. Hypertension 55 (3), 579–592. 10.1161/hypertensionaha.109.134205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Shioi A., Nishizawa Y., Jono S., Koyama H., Hosoi M., Morii H. (1995). β-Glycerophosphate Accelerates Calcification in Cultured Bovine Vascular Smooth Muscle Cells. Atvb 15 (11), 2003–2009. 10.1161/01.atv.15.11.2003 [DOI] [PubMed] [Google Scholar]
  42. Shobeiri N., Adams M. A., Holden R. M. (2010). Vascular Calcification in Animal Models of CKD: A Review. Am. J. Nephrol. 31 (6), 471–481. 10.1159/000299794 [DOI] [PubMed] [Google Scholar]
  43. Singh A., Tandon S., Tandon C. (2021). An Update on Vascular Calcification and Potential Therapeutics. Mol. Biol. Rep. 48 (1), 887–896. 10.1007/s11033-020-06086-y [DOI] [PubMed] [Google Scholar]
  44. Song Y., Hou M., Li Z., Luo C., Ou J.-S., Yu H., et al. (2017). TLR4/NF-κB/Ceramide Signaling Contributes to Ox-LDL-Induced Calcification of Human Vascular Smooth Muscle Cells. Eur. J. Pharmacol. 794, 45–51. 10.1016/j.ejphar.2016.11.029 [DOI] [PubMed] [Google Scholar]
  45. Speer M. Y., Yang H.-Y., Brabb T., Leaf E., Look A., Lin W.-L., et al. (2009). Smooth Muscle Cells Give Rise to Osteochondrogenic Precursors and Chondrocytes in Calcifying Arteries. Circ. Res. 104 (6), 733–741. 10.1161/CIRCRESAHA.108.183053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Stabley J. N., Towler D. A. (2017). Arterial Calcification in Diabetes Mellitus. Atvb 37 (2), 205–217. 10.1161/ATVBAHA.116.306258 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Van Eck N. J., Waltman L. (2010). Software Survey: VOSviewer, a Computer Program for Bibliometric Mapping. Scientometrics 84 (2), 523–538. 10.1007/s11192-009-0146-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Watanabe S., Fujii H., Kono K., Watanabe K., Goto S., Nishi S. (2020). Influence of Oxidative Stress on Vascular Calcification in the Setting of Coexisting Chronic Kidney Disease and Diabetes Mellitus. Sci. Rep. 10 (1), 20708. 10.1038/s41598-020-76838-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Yan J., Stringer S. E., Hamilton A., Charlton-Menys V., Götting C., Müller B., et al. (2011). Decorin GAG Synthesis and TGF-β Signaling Mediate Ox-LDL-Induced Mineralization of Human Vascular Smooth Muscle Cells. Arterioscler Thromb. Vasc. Biol. 31 (3), 608–615. 10.1161/ATVBAHA.110.220749 [DOI] [PubMed] [Google Scholar]
  50. Yang P., Troncone L., Augur Z. M., Kim S. S. J., McNeil M. E., Yu P. B. (2020). The Role of Bone Morphogenetic Protein Signaling in Vascular Calcification. Bone 141, 115542. 10.1016/j.bone.2020.115542 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Yu D., Pan T. (2021). Tracing Knowledge Diffusion of TOPSIS: A Historical Perspective from Citation Network. Expert Syst. Appl. 168, 114238. 10.1016/j.eswa.2020.114238 [DOI] [Google Scholar]
  52. Yuan X., Bhat O. M., Samidurai A., Das A., Zhang Y., Li P.-L. (2020). Reversal of Endothelial Extracellular Vesicle-Induced Smooth Muscle Phenotype Transition by Hypercholesterolemia Stimulation: Role of NLRP3 Inflammasome Activation. Front. Cel Dev. Biol. 8, 597423. 10.3389/fcell.2020.597423 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Zeng P., Yang J., Liu L., Yang X., Yao Z., Ma C., et al. (2021). ERK1/2 Inhibition Reduces Vascular Calcification by Activating miR-126-3p-Dkk1/lrp6 Pathway. Theranostics 11 (3), 1129–1146. 10.7150/thno.49771 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Zhang X., Li Y., Yang P., Liu X., Lu L., Chen Y., et al. (2020). Trimethylamine-N-Oxide Promotes Vascular Calcification through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-Κb (Nuclear Factor κB) Signals. Atvb 40 (3), 751–765. 10.1161/ATVBAHA.119.313414 [DOI] [PubMed] [Google Scholar]
  55. Zheng K., Wang X. (2019). Publications on the Association between Cognitive Function and Pain from 2000 to 2018: A Bibliometric Analysis Using CiteSpace. Med. Sci. Monit. 25, 8940–8951. 10.12659/MSM.917742 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Zhu Y., Han X.-Q., Sun X.-J., Yang R., Ma W.-Q., Liu N.-F. (2020). Lactate Accelerates Vascular Calcification through NR4A1-Regulated Mitochondrial Fission and BNIP3-Related Mitophagy. Apoptosis 25 (5-6), 321–340. 10.1007/s10495-020-01592-7 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES